Drugs / DB-1310
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06220864 | Feb 2024 → Dec 2027 expected | neoplasm | Synnovation Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05785741 | Aug 2023 → Dec 2027 expected | neoplasm | DualityBio Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DB-1310 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05785741 ↗ |
| Route | Intravenous | “Administered I.V.” NCT05785741 ↗ |